Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
Phase 4 N=12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
N/A N=44 Blood Flow and Bone Density in Healthy Adult Women
Bone Loss · Hypotensive · Lower Limb Fluid Pooling
Primary: Bone Density of Proximal Femur — -0.133; -.675; 1.3 percent change in bone density
Phase 3 N=424 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
Phase 2 N=412 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms — -0.81; 4.41; 4.71; 6.69 Percent change — p=<0.001
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
N/A N=7,749 Patient Activation After DXA Result Notification
Osteoporosis · Bone Diseases, Metabolic
Primary: Guideline Concordant Osteoporosis Therapy — 2537; 2477 Participants
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 2 N=419 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density · Postmenopausal Osteoporosis
Primary: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine — -0.1; 4.1; 7.1; 5.4 percent change — p=< 0.0001
N/A N=138 Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial
Crohn Disease
Primary: Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months — 0.15; 0.23 Z-score — p=0.38
Phase 2 N=208 The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women
Bone Resorption · Osteoporosis
Primary: Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline — 0.51; 0.51 percentage change
N/A N=36 Texture Analysis for Postmenopausal Osteoporosis
Osteoporosis · Osteopenia
Primary: Changes in Lumbar Spine BMD +/- Treatment With Alendronate — 5.28; -1.48 Percent Change
Phase 3 N=30 Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
Bone Density · Bone Loss · Anorexia Nervosa
Primary: Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) — 0.90; 0.87 g/cm^2 — p=0.009
Phase 2 N=247 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Postmenopausal Osteoporosis
Primary: Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12 — 2.4; 3.4; -.8 Percent Change from Baseline
Phase 2 N=52 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents
HIV Infection
Primary: Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD — 14.4; 5.5; 15.9; 7.1 Percent change from baseline — p=<0.001
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=94 Bone Health in Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Primary: Bone Mineral Density in FSHD — -0.4 z-score
Phase 4 N=52 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
HIV · Osteopenia · Osteoporosis
Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine and Hips — 2.7; 3.0; 2.3; 1.9 percent change — p=<0.0001
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
N/A N=9 Exercise Mode and Acute Bone Resorption
Osteoporosis · Aging
Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
Phase 2 N=171 Green Tea and Tai Chi for Bone Health
Osteoporosis
Primary: Change From Baseline (100%) in Ratio of Bone Formation Marker to Bone Resorption Marker — 106.1; 103.6; 112.3; 113.0 percentage change from baseline